Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study.
Mohamed Gomaa KamelAmr Ehab El-QushayriAhmed Kamal SayedNguyen Tien HuyPublished in: Journal of comparative effectiveness research (2020)
Background: Nodal mantle cell lymphoma (NMCL) has a worse survival than extra-nodal mantle cell lymphoma. Materials & methods: A cohort study was conducted to evaluate the primary site role as a mortality predictor using data from 1983 to 2011 from the Surveillance, Epidemiology, and End Results (SEER) database. Results: Most patients had NMCL in multiple regions (71.9%). There was a significantly increased incidence of NMCL cases over years with 83.2% of them occurred between 1998 and 2011. The mean survival was 52.9 months with overall survival/cancer-specific survival rate of 29.2/42.9%, respectively. Lymph nodes of intrathoracic and multiple regions had a worse overall survival while the head, face and neck, intra-abdominal, pelvic, inguinal region and leg as well as multiple regions had worse cancer-specific survival. Conclusion: NMCL primary site can serve as a prognostic factor. We encourage adding it to MCL International Prognostic Index.
Keyphrases
- lymph node
- prognostic factors
- free survival
- papillary thyroid
- risk factors
- neoadjuvant chemotherapy
- prostate cancer
- cardiovascular disease
- emergency department
- newly diagnosed
- public health
- squamous cell carcinoma
- chronic kidney disease
- electronic health record
- cardiovascular events
- radiation therapy
- coronary artery disease
- adverse drug
- lymph node metastasis
- drug induced
- data analysis